Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split is aimed at regaining compliance with Nasdaq listing requirements.
The Company's common stock is expected to begin trading on a split-adjusted basis on August 18, 2025.
Purpose of Reverse Stock Split
To maintain the Nasdaq listing and enhance shareholder value.
Effect of Reverse Stock Split
Combining every 3 shares into 1 to reduce outstanding shares.
Shareholder Benefit
Stockholders entitled to receive cash instead of fractional shares.
- The reverse stock split is a strategic move to meet the minimum bid price requirement for Nasdaq listing.
- Reducing outstanding shares can impact the stock price and market perception of the Company.
Entero Therapeutics, Inc.'s reverse stock split decision reflects its commitment to maintaining market visibility and shareholder value. The stock adjustment is a significant step towards compliance with Nasdaq regulations.